Manufacturer of the drug Vorinostat

In 2006, the U.S. Food and Drug Administration (FDA) approved subhydroxamic acid, a pan-histone deacetylase inhibitor (HDACi), for patients with cutaneous T-cell lymphoma (CTCL). Vorinostat, marketed by Merck asZolinza, appears to exert immunomodulatory effects by acting on cancer and immune cells. Similar to other targeted anticancer drugs, vorinostat was developed based on the hypothesis that it could mediate direct cytotoxic effects on malignant cells. Vorinostat has immunosuppressive side effects. It has been reported that vorinostat has been found to inhibit the expression of the immunosuppressive cytokine interleukin 1033 and inhibit the cytotoxic effect of NK cells.